CTOR: מקדם מחיר להכנסות Citius Oncology Inc
The P/S ratio of Citius Oncology, Inc. (CTOR) reflects current dynamics, with the latest value recorded as 7.60. Experienced executives are effectively implementing innovative therapy methods. Profit growth is driven by patents for high-margin antineoplastic drugs. Development stability is maintained through the strategic outsourcing of clinical trials to external contractors under strict internal control.
פילוחי מדדים ואנליטיקה של חברת Citius Oncology, Inc (CTOR)
The P/S multiple compares market capitalization to revenue, allowing for an assessment of the value of each unit of sales and the identification of market anomalies. For Citius Oncology, Inc. (CTOR), which holds exclusive patented technologies in blood cancer therapy, the price-to-sales multiple reflects the potential for high asset premiums, where the stability of the chart confirms the company's fundamental resilience in the absence of effective market analogues.
